PLEASANTON, Calif. - 10x Genomics, Inc. (NASDAQ:TXG) announced today the acquisition of Proteintech Genomics, a division within Proteintech Group that develops high-plex proteomic solutions for single cell and spatial applications on 10x platforms, according to a press release statement.
The acquisition adds Proteintech Genomics’ technologies to 10x’s proteomics capabilities, including the Human Discovery Panel, an antibody-based single cell protein panel designed for integrated analysis of intracellular proteins, cell surface proteins and transcriptomic profiles within sequencing-compatible workflows. The panel is compatible with Flex chemistry, including the Flex Apex assay.
"We believe the future of biological analysis will increasingly integrate transcriptomic and proteomic information at the single cell and spatial levels," said Michael Schnall-Levin, Chief Technology Officer, Chief Strategy Officer and Founding Scientist of 10x Genomics.
Proteintech Genomics’ protein panels were built for 10x single cell workflows and are used by researchers to simultaneously analyze RNA and protein. The acquisition combines 10x’s single cell and spatial biology platforms with Proteintech Genomics’ protein detection capabilities.
"From day one, Proteintech Genomics was built around the belief that RNA and protein measurements are most powerful when used together," said Dr. Kristopher Nazor, CEO of Proteintech Genomics.
The financial terms of the transaction were not disclosed. 10x Genomics stated the transaction will not meaningfully impact its near-term financial outlook.The acquisition comes as 10x Genomics maintains a solid financial position with a market capitalization of $3.7 billion and strong liquidity metrics. According to InvestingPro data, the company holds more cash than debt on its balance sheet and maintains a current ratio of 5.9, providing flexibility for strategic investments. The stock has delivered exceptional returns with a 189% gain over the past year, though InvestingPro analysis suggests the shares are currently trading above their Fair Value. Investors seeking deeper insights can access comprehensive analysis through the company’s Pro Research Report, available for TXG and 1,400+ other US equities.
10x Genomics develops instruments, consumables and software for single cell and spatial biology used by academic and translational researchers and biopharmaceutical companies.
In other recent news, 10x Genomics announced the results of its annual meeting where shareholders elected three Class I directors to serve three-year terms. Meanwhile, William Blair upgraded 10x Genomics to an "Outperform" rating, highlighting the company’s role in AI-driven drug discovery and its consistent top-line performance. In a collaborative effort, Bioptimus and 10x Genomics launched the Spatial Tissue Embedding Learning Atlas, aiming to profile up to 100,000 patient tissue specimens globally.
However, concerns arose after Microsoft’s announcement of an AI model that could impact demand for spatial proteomics, as noted by Wolfe Research. Additionally, 10x Genomics faced a significant stock sell-off after ARK Invest sold over 473,000 shares, signaling a shift in investment strategy. This move by ARK Invest has raised concerns about potential reductions in holdings by other institutional investors. These developments reflect the dynamic changes and challenges facing 10x Genomics in the current market landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Before you click "buy," know exactly where to set your stop-loss. Our Vision AI literally "sees" your TXG chart and delivers a complete risk management plan—entry, stop-loss, and profit target—in under 60 seconds.Protect your downside. Validate every trade. Invest smarter.